These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 10652233)

  • 1. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis.
    Masugi J; Tamori Y; Mori H; Koike T; Kasuga M
    Biochem Biophys Res Commun; 2000 Feb; 268(1):178-82. PubMed ID: 10652233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of adipogenesis by a COOH-terminally truncated mutant of PPARgamma2 in 3T3-L1 cells.
    Masugi J; Tamori Y; Kasuga M
    Biochem Biophys Res Commun; 1999 Oct; 264(1):93-9. PubMed ID: 10527847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes.
    Mukherjee R; Hoener PA; Jow L; Bilakovics J; Klausing K; Mais DE; Faulkner A; Croston GE; Paterniti JR
    Mol Endocrinol; 2000 Sep; 14(9):1425-33. PubMed ID: 10976920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YM268 increases the glucose uptake, cell differentiation, and mRNA expression of glucose transporter in 3T3-L1 adipocytes.
    Shimaya A; Kurosaki E; Shioduka K; Nakano R; Shibasaki M; Shikama H
    Horm Metab Res; 1998 Sep; 30(9):543-8. PubMed ID: 9808320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stage-specific effects of a thiazolidinedione on proliferation, differentiation and PPARgamma mRNA expression in 3T3-L1 adipocytes.
    Takamura T; Nohara E; Nagai Y; Kobayashi K
    Eur J Pharmacol; 2001 Jun; 422(1-3):23-9. PubMed ID: 11430909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of peroxisome proliferator-activated receptor-gamma in maintenance of the characteristics of mature 3T3-L1 adipocytes.
    Tamori Y; Masugi J; Nishino N; Kasuga M
    Diabetes; 2002 Jul; 51(7):2045-55. PubMed ID: 12086932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation.
    Burris TP; Pelton PD; Zhou L; Osborne MC; Cryan E; Demarest KT
    Mol Endocrinol; 1999 Mar; 13(3):410-7. PubMed ID: 10076998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abietic acid activates peroxisome proliferator-activated receptor-gamma (PPARgamma) in RAW264.7 macrophages and 3T3-L1 adipocytes to regulate gene expression involved in inflammation and lipid metabolism.
    Takahashi N; Kawada T; Goto T; Kim CS; Taimatsu A; Egawa K; Yamamoto T; Jisaka M; Nishimura K; Yokota K; Yu R; Fushiki T
    FEBS Lett; 2003 Aug; 550(1-3):190-4. PubMed ID: 12935909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis.
    Gurnell M; Wentworth JM; Agostini M; Adams M; Collingwood TN; Provenzano C; Browne PO; Rajanayagam O; Burris TP; Schwabe JW; Lazar MA; Chatterjee VK
    J Biol Chem; 2000 Feb; 275(8):5754-9. PubMed ID: 10681562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma.
    De Vos P; Lefebvre AM; Miller SG; Guerre-Millo M; Wong K; Saladin R; Hamann LG; Staels B; Briggs MR; Auwerx J
    J Clin Invest; 1996 Aug; 98(4):1004-9. PubMed ID: 8770873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAT5A: a partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic.
    Misra P; Chakrabarti R; Vikramadithyan RK; Bolusu G; Juluri S; Hiriyan J; Gershome C; Rajjak A; Kashireddy P; Yu S; Surapureddi S; Qi C; Zhu YJ; Rao MS; Reddy JK; Ramanujam R
    J Pharmacol Exp Ther; 2003 Aug; 306(2):763-71. PubMed ID: 12730351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity.
    Schupp M; Janke J; Clasen R; Unger T; Kintscher U
    Circulation; 2004 May; 109(17):2054-7. PubMed ID: 15117841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene.
    Schoonjans K; Peinado-Onsurbe J; Lefebvre AM; Heyman RA; Briggs M; Deeb S; Staels B; Auwerx J
    EMBO J; 1996 Oct; 15(19):5336-48. PubMed ID: 8895578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiazolidinedione- and tumor necrosis factor alpha-induced downregulation of peroxisome proliferator-activated receptor gamma mRNA in differentiated 3T3-L1 adipocytes.
    Perrey S; Ishibashi S; Yahagi N; Osuga J; Tozawa R; Yagyu H; Ohashi K; Gotoda T; Harada K; Chen Z; Iizuka Y; Shionoiri F; Yamada N
    Metabolism; 2001 Jan; 50(1):36-40. PubMed ID: 11172472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential gene regulation by PPARgamma agonist and constitutively active PPARgamma2.
    Li Y; Lazar MA
    Mol Endocrinol; 2002 May; 16(5):1040-8. PubMed ID: 11981038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPARgamma induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPalpha during the conversion of 3T3 fibroblasts into adipocytes.
    Wu Z; Xie Y; Morrison RF; Bucher NL; Farmer SR
    J Clin Invest; 1998 Jan; 101(1):22-32. PubMed ID: 9421462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation.
    Adams M; Montague CT; Prins JB; Holder JC; Smith SA; Sanders L; Digby JE; Sewter CP; Lazar MA; Chatterjee VK; O'Rahilly S
    J Clin Invest; 1997 Dec; 100(12):3149-53. PubMed ID: 9399962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel potent antagonist of peroxisome proliferator-activated receptor gamma blocks adipocyte differentiation but does not revert the phenotype of terminally differentiated adipocytes.
    Camp HS; Chaudhry A; Leff T
    Endocrinology; 2001 Jul; 142(7):3207-13. PubMed ID: 11416043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity.
    Rieusset J; Touri F; Michalik L; Escher P; Desvergne B; Niesor E; Wahli W
    Mol Endocrinol; 2002 Nov; 16(11):2628-44. PubMed ID: 12403851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPARgamma activators down-regulate the expression of PPARgamma in 3T3-L1 adipocytes.
    Camp HS; Whitton AL; Tafuri SR
    FEBS Lett; 1999 Mar; 447(2-3):186-90. PubMed ID: 10214942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.